JP6587288B2 - がん幹細胞の同定ならびに診断および処置のためのその使用 - Google Patents

がん幹細胞の同定ならびに診断および処置のためのその使用 Download PDF

Info

Publication number
JP6587288B2
JP6587288B2 JP2016574232A JP2016574232A JP6587288B2 JP 6587288 B2 JP6587288 B2 JP 6587288B2 JP 2016574232 A JP2016574232 A JP 2016574232A JP 2016574232 A JP2016574232 A JP 2016574232A JP 6587288 B2 JP6587288 B2 JP 6587288B2
Authority
JP
Japan
Prior art keywords
cells
tumor
population
cancer
passages
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016574232A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017528114A (ja
JP2017528114A5 (OSRAM
Inventor
ベンジャミン デケル
ベンジャミン デケル
オリット ハラリ−スタインバーグ
オリット ハラリ−スタインバーグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sheba Impact Ltd
Original Assignee
Sheba Impact Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sheba Impact Ltd filed Critical Sheba Impact Ltd
Publication of JP2017528114A publication Critical patent/JP2017528114A/ja
Publication of JP2017528114A5 publication Critical patent/JP2017528114A5/ja
Application granted granted Critical
Publication of JP6587288B2 publication Critical patent/JP6587288B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90203—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
JP2016574232A 2014-06-25 2015-06-25 がん幹細胞の同定ならびに診断および処置のためのその使用 Expired - Fee Related JP6587288B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462016773P 2014-06-25 2014-06-25
US62/016,773 2014-06-25
PCT/IL2015/050663 WO2015198334A2 (en) 2014-06-25 2015-06-25 Identification of cancer stem cells and use of same for diagnosis and treatment

Publications (3)

Publication Number Publication Date
JP2017528114A JP2017528114A (ja) 2017-09-28
JP2017528114A5 JP2017528114A5 (OSRAM) 2018-08-09
JP6587288B2 true JP6587288B2 (ja) 2019-10-09

Family

ID=53674236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016574232A Expired - Fee Related JP6587288B2 (ja) 2014-06-25 2015-06-25 がん幹細胞の同定ならびに診断および処置のためのその使用

Country Status (11)

Country Link
US (1) US10883994B2 (OSRAM)
EP (1) EP3161480B1 (OSRAM)
JP (1) JP6587288B2 (OSRAM)
KR (1) KR20170041192A (OSRAM)
CN (1) CN106537148B (OSRAM)
AU (1) AU2015278659A1 (OSRAM)
CA (1) CA2953663A1 (OSRAM)
ES (1) ES2791199T3 (OSRAM)
IL (1) IL249741B (OSRAM)
SG (1) SG11201610630RA (OSRAM)
WO (1) WO2015198334A2 (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2953663A1 (en) 2014-06-25 2015-12-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. Identification of cancer stem cells and use of same for diagnosis and treatment
US11573241B2 (en) 2016-03-09 2023-02-07 Institute National De La Sante Et De La Recherche Medicale (Inserm) Total cellular iron as a marker of cancer stem cells and uses thereof
CN108967358A (zh) * 2018-05-31 2018-12-11 上海交通大学医学院附属瑞金医院 一种斑马鱼fl肿瘤模型的构建方法及其应用
KR20200109544A (ko) * 2019-03-13 2020-09-23 울산대학교 산학협력단 공통 유전자 추출에 의한 다중 암 분류 방법
KR102400464B1 (ko) * 2020-07-28 2022-05-19 부산대학교 산학협력단 암 줄기세포 검출용 바이오 마커 조성물
CN114624304B (zh) * 2021-12-09 2023-09-19 重庆医科大学国际体外诊断研究院 基于铈银纳米花和分支DNAzyme步行器的miRNA电化学传感器

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5204096A (en) 1984-03-07 1993-04-20 New York Blood Center, Inc. Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipid vesicle carriers
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5258499A (en) 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5935850A (en) 1996-09-30 1999-08-10 The Research Foundation Of State University Of New York Model for cell migration and use thereof
US6037137A (en) 1997-02-20 2000-03-14 Oncoimmunin, Inc. Fluorogenic peptides for the detection of protease activity
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
TW200422749A (en) 2003-04-22 2004-11-01 Adv Lcd Tech Dev Ct Co Ltd Crystallization apparatus, crystallization method, phase modulation element, device and display apparatus
US20070021365A1 (en) * 2005-06-21 2007-01-25 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto
EP2109668A4 (en) * 2007-01-22 2011-10-05 Macrogenics West Inc HUMAN CANCER STEM CELLS
EP2022848A1 (en) * 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
CA2715036A1 (en) * 2008-03-14 2009-09-17 Retrotope, Inc. Therapies for cancer using isotopically substituted lysine
EP2263072A1 (en) 2008-03-26 2010-12-22 Veritide Limited An analysis system
US20110111434A1 (en) * 2008-07-15 2011-05-12 Huang Emina H Colon stem cells associated with colitisand colorectal cancer and methods of use
EP2465920B1 (en) 2009-02-26 2017-04-12 Tel HaShomer Medical Research Infrastructure and Services Ltd. Isolated populations of renal stem cells and methods of isolating and using same
US20120070450A1 (en) * 2009-03-24 2012-03-22 Riken Leukemia stem cell markers
SG189212A1 (en) 2010-09-03 2013-05-31 Stem Centrx Inc Identification and enrichment of cell subpopulations
EP2772268B8 (en) * 2011-10-28 2020-01-08 Chugai Seiyaku Kabushiki Kaisha Cancer stem cell-specific molecule
CA2953663A1 (en) 2014-06-25 2015-12-30 Tel Hashomer Medical Research Infrastructure And Services Ltd. Identification of cancer stem cells and use of same for diagnosis and treatment

Also Published As

Publication number Publication date
WO2015198334A2 (en) 2015-12-30
AU2015278659A1 (en) 2017-02-02
IL249741A0 (en) 2017-02-28
KR20170041192A (ko) 2017-04-14
SG11201610630RA (en) 2017-01-27
EP3161480B1 (en) 2020-02-12
CN106537148B (zh) 2019-10-11
JP2017528114A (ja) 2017-09-28
WO2015198334A3 (en) 2016-02-25
CA2953663A1 (en) 2015-12-30
US20170199195A1 (en) 2017-07-13
US10883994B2 (en) 2021-01-05
EP3161480A2 (en) 2017-05-03
IL249741B (en) 2019-12-31
ES2791199T3 (es) 2020-11-03
CN106537148A (zh) 2017-03-22

Similar Documents

Publication Publication Date Title
JP6912538B2 (ja) 血中循環腫瘍細胞に関する方法およびアッセイ
Hosein et al. Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution
Krawczyk et al. Expression of stem cell and epithelial‐mesenchymal transition markers in circulating tumor cells of breast cancer patients
EP2406397B1 (en) Methods using axl as a biomarker of epithelial-to-mesenchymal transition
Kislin et al. NHERF-1: modulator of glioblastoma cell migration and invasion
CN106537148B (zh) 癌症干细胞的鉴定及其用于诊断和治疗的用途
Abreu de Oliveira et al. Wnt/β-catenin inhibition disrupts carboplatin resistance in isogenic models of triple-negative breast cancer
Moyes et al. Effects of tumor grade and dexamethasone on myeloid cells in patients with glioma
Li et al. Single‐cell transcriptomic analysis of glioblastoma reveals pericytes contributing to the blood–brain–tumor barrier and tumor progression
US9103819B2 (en) Peripheral zone tumor cells, methods for their preparation and use
US20170030916A1 (en) Materials and methods for diagnosing and predicting the course of prostate cancer
Martínková et al. Ribosome transfer via tunnelling nanotubes rescues protein synthesis in pancreatic cancer cells
Strobbe et al. Mitochondrial sites of contact with the nucleus aid in chemotherapy evasion of glioblastoma cells
Strobbe et al. Nucleus Associated Mitochondria (NAM) unveil a cholesterol mediated mechanism of Temozolomide resistance in glioblastoma cells.
Jamieson Targeting WNT5A-Mediated Therapy Resistance Mechanisms and Tumor Genomic Heterogeneity in Lethal Bone Metastatic Prostrate Cancer
WO2012110425A1 (en) Methods for monitoring the response to treatment and for treating colorectal cancer
Li Targeting CXCR2+ Neuroendocrine-like Cells for the Treatment of Castration-resistant Prostate Cancer
Hurst NF-kappaB function and activation in mouse mammary stem cells and its interplay with the downstream target, cIAP2 in MMTV-ErbB2 induced tumourigenesis

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20170719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180622

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180622

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190412

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190718

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190813

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190905

R150 Certificate of patent or registration of utility model

Ref document number: 6587288

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees